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comparing A and B (Salanti et al., 2008a).
The average of CUs for all possible
comparisons in a network yields the
C-score. A larger C-score implies a grea-
ter degree of co-occurrence, either predi-
lection or aversion, for particular head-to-
head comparisons. C-scores are interpre-
ted with statistical significance, with
Po0.05 considered significant. The three
trial networks studied by Maruani et al.
(2014) demonstrated no significant co-
occurrence.
Use in dermatology
Another example of the application of
network geometry in the field of derma-
tology is Kim et al.’s (2014) investigation
of treatment modalities for basal cell
carcinoma (BCC). Using a study design
similar to that used by Maruani et al.
(2014), three classes of interventions for
BCC were compared: surgical, destruc-
tive, and topical. Despite a plethora of
treatments for BCC, there was a sub-
stantial lack of head-to-head trials, with
almost exclusive use of placebos or
comparison of one agent against itself
(e.g., at a different dose). The geometric
pattern resembles those of chronic lower
extremity wounds in the paper by
Maruani et al. (2014), with multiple
lines emanating from a common
comparator. Destructive and surgical
treatments were rarely compared with
topical treatments.
Other applications
One of the foundational applications of
network theory was Leonard Euler’s
1736 proof regarding the seven bridges
of Konigsberg (modern day Prussia;
Pryor and Sleigh, 2011). Euler proved
the non-existence of what is now refer-
red to as a Euler path, a continuous path
passing to each node through each edge
once and only once. More importantly,
Euler’s proof set an example of solving a
real-world problem by distilling it into
an abstract topological graph. Network
theory has innumerable applications in
the modern day. In the basic sciences,
network theory is used to model
biological systems, such as transcription
factor circuitry and various metabolic
pathways (Baraba´si et al., 2011). It has
also been used widely in social sciences
to model social interactions between
groups and individuals. The World
Wide Web is the largest example of
network topology, with over one billion
nodes representing webpages and edges
representing hyperlinks or URLs (Albert
and Barabasi, 2002).
Conclusion
Network theory is a powerful tool that
provides visual representations of com-
plex structures. Maruani et al. (2014)
have applied this modality brilliantly to
dermatological treatments in an effort to
reduce research gaps identified by the
CER initiative. In an ideal world case,
head-to-head comparisons would be
performed when a multitude of health-
care interventions exist for a particular
disease. A strong evidence base best
informs treatment decisions for greatest
patient benefit. Network geometry is an
emerging model to accomplish this
method investigation and analysis.
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Diagnosis by Numbers: Defining Skin
Disease Pathogenesis through
Collated Gene Signatures
Amr Salam1 and John A. McGrath1
Disease gene expression profiles can be utilized as biomarkers for diagnostic,
prognostic, and targeted therapeutic purposes, although individual data sets may
be of limited generic value. To develop broader clinical relevance from disease
gene signatures, Inkeles et al. demonstrate how mining publically available
microarray data from a range of skin disorders can elucidate disease pathways,
generate a multi-disease classifier, and identify potential therapeutic targets. This
integrative molecular classification and functional analysis offers a new approach
to understanding disease pathogenesis, with significant implications for
diagnostics and the development of personalized medicine.
Journal of Investigative Dermatology (2015) 135, 17–19; doi:10.1038/jid.2014.389
DNA microarrays work on the principle
that complementary strands of nucleic
acid bind together, and the use of arrays
has proven invaluable through the ability
to examine expression of thousands of
genes simultaneously. It is now almost
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20 years since the development of
microarray methods to measure diffe-
rential gene expression (Schena et al.,
1995; Lockhart et al., 1996), and the
technology has advanced enormously
thereafter, with the creation of RNA-
sequence in 2008 (Wang et al., 2009),
and more recently single cell transcri-
ptomic analysis (Shalek et al., 2014), as
well as new methodology that can even
localize specific transcripts within
individual cells (Lee et al., 2014). Initial
concerns in the 1990s about multiple
different platforms, probe design, and
internal controls and standards have
gradually eased with improved concor-
dance of data and widespread laboratory
experience (Kawasaki 2005). Moreover,
gene expression profiling technology has
afforded the opportunity to study
disease-specific genes in detail and to
discover pivotal new data concerning
disease processes and pathways. Never-
theless, most human studies, certainly
within dermatology, have tended to
compare a single disease with appro-
priate controls, or perhaps two different
skin diseases. Such approaches may
generate comparative insights but are
not ideal in identifying data germane to
understanding pathogenic mechanisms
that may be disease specific or shared
with other disorders.
Some studies in investigative derma-
tology have tried to address this shortfall.
For example, Kamsteeg et al. (2010)
used real-time quantitative PCR, imm-
unohistochemistry, and bioinformatics to
study gene expression from the epide-
rmis in various forms of eczema (atopic
dermatitis, allergic contact dermatitis,
and irritant contact dermatitis), in com-
parison with psoriasis and normal skin.
The investigators found that by analyzing
the expression levels of seven genes, the
type of inflammatory response could be
reliably predicted with a multi-disease
classifier. However, in reality, the
differential diagnosis of such lesions
could include a broader range of
other inflammatory dermatoses, as
well as some infective and neoplastic
conditions, thus limiting clinical
precision. This type of study also has a
high error rate and the impact of disease
severity may further skew interpretation
and restrict clinical application.
Inkeles et al. (2014)
demonstrate that gene
expression profiles from
a single disease, despite
being derived from inde-
pendent data sets, nearly
always cluster together
into groups with related
pathogenesis, findings
that may improve
clinical diagnosis of skin
disorders.
Generation of multi-disease classifiers
to accurately diagnose skin diseases
In this issue of the Journal, Inkeles et al.
(2014) present a somewhat different
methodology to assess gene signatures
in the context of skin disease
diagnostics. The concept was not to
generate new data but to mine the
plethora of existing data that can be
accessed readily online. The NCBI
Gene Expression Omnibus (GEO) is a
rich source of gene expression data
that can be easily and openly viewed
(http://www.ncbi.nlm.nih.gov/geo/). Most
journals, including the Journal of
Investigative Dermatology, require
authors of new work to deposit gene
expression data in a repository such as
GEO, thus making the data available to
all. The approach taken in this new
study was to collect and examine
publically available gene expression
data from 311 skin biopsy specimens
from 16 inflammatory, infectious, and
neoplastic disorders and to use the
data to construct a disease classifier.
Their study normalized samples to a
standard reference set of microarrays
and thereby eliminated the need for
control samples in each data set. The
authors designed a random forest
classifier that, based on the expression
of a limited number of genes, could
accurately predict disease diagnosis
with 92% sensitivity and over 99%
specificity. For validation, the classifier
was further assessed using 194 indepen-
dent samples: sensitivity and specificity
remained unchanged. Inkeles et al.
(2014) also provide select examples
into the clinical application of such a
classifier. In one case, biopsies taken
from a patient ambiguously diagnosed
with atopic dermatitis were later
diagnosed as psoriasis by the classifier.
The patient subsequently went on to
develop characteristic inflammatory
psoriatic plaques confirming the classi-
fier label and modifying the original
clinical diagnosis.
Multi-disease classifiers provide insight
into disease pathogenesis
Inkeles et al. (2014) demonstrate that
gene expression profiles from the same
diseases, despite being derived from
independent data sets, nearly always
cluster together into groups with
related pathogenesis, findings that may
improve clinical diagnosis of skin
disorders. Using this model, the same
finding was also true for normal skin
samples from different batches. For
further analysis in the disease cohorts,
T helper type 1 versus T helper type 2
cytokine profiles were interrogated.
The authors examined IFN gene
expression profiles, but as these are
only weakly detected on microarrays
data were derived from Type I and
Type-II-specific-induced transcriptional
Clinical Implications
 An improved understanding of the pathogenesis of several skin diseases
can be obtained from integration of multiple publically available gene
expression data sets.
 Comparing gene signatures of multiple diseases from multiple sources is
valid using normalized data tools such as Frozen Robust Multi-array Average.
 Gene signature data from multi-disease classifiers have the potential to
improve diagnostics for skin disease and to identify optimal therapeutic
targets for stratified or personalized medicine.
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profiles of peripheral blood mono-
nuclear cells to determine IFN signa-
tures. Across the 16 different skin
conditions there was an inverse
correlation between IFN-b and IFN-g,
notably with particular diseases
mapping to reproducible ratios—and
thus offering molecular signposts to dis-
ease diagnostics. Collectively, the data
provide valuable insight into the mole-
cular processes that underlie various
diseases and furthermore infer that simi-
lar processes underpin diseases from the
same disease classifier.
Multi-disease classifiers, disease
classification, and the development of
personalized medicine
The core ethos underpinning the con-
cept of personalized medicine is ‘‘right
patient, right drug, right dose, at the
right time’’. The integrative molecular
classification, as well as the functional
analysis, outlined in the study by Inkeles
et al. (2014), offers a valuable tool in
bringing personalized medicine closer
to the clinical frontline. Although it is
tempting to jump ahead and speculate
about how multi-disease classifiers
could be used to identify novel
biomarkers and therapeutic targets for
skin diseases, the current emphasis has
to be on improving understanding of
disease pathogenesis, implementing best
clinical practice, and reflecting on
whether current knowledge on disease
classification and pathophysiology is
matched by the multi-disease classifier
data. Dermatology, and medicine in
general, is littered with inappropriate
(or frankly wrong) disease sub-
groupings. For example, 150 years ago
epidermolysis bullosa and urticaria were
thought to be similar diseases, and even
in current practice, we still categorize
different keratin genodermatoses as
either mechanobullous diseases or
forms of ichthyosis, despite the well
characterized shared pathogenic
overlap of keratin intermediate filament
mutations and keratinocyte cytolysis. For
inflammatory dermatoses, the dermato-
logical literature contains numerous
reports of imprecise entities such as
‘‘psoriasiform eczema’’ or ‘‘eczematoid-
lichenoid eruption’’, but the data mining
approach advocated by Inkeles et al.
(2014) has the potential to help resolve
such issues, or at least offer fresh insight
into discrete or shared disease pathogen-
eses. However, perhaps stories of
common disease pathogenesis only
tend to become more relevant when
therapies are introduced or challenged.
The multi-disease classifier data presen-
ted by Inkeles et al. (2014) offer both a
reality check and a glimpse into how
personal diagnostics and therapeutics
might develop. The study also high-
lights the considerable resources on
gene expression data that are freely
accessible in the public domain, and
the value of thinking beyond the traditio-
nal disease-control experiment. There
remains a rich seam of widely avai-
lable skin disease gene signature data
still available to mine, with significant
potential benefits in store for the future
classification and improved treatment of
diseases in dermatology.
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Healing Refractory Venous Ulcers:
New Treatments Offer Hope
Robert S. Kirsner1, Katherine L. Baquerizo Nole1, Joshua D. Fox1 and
Sophia N. Liu1
Non-healing wounds are associated with an inflammatory and proteolytic wound
environment, and recent therapeutic strategies have been focused on reversing
these changes. Connexins, as members of gap junctions, are important in
intercellular signaling and wound repair. Connexin 43 (Cx43) downregulation is
associated with normal wound healing, and it has been found to be upregulated
in non-healing venous leg ulcers (VLUs). Ghatnekar et al. (2014) report findings of
a small phase II trial performed in Indian patients with chronic VLUs, reporting
that ACT1, a mimetic peptide of Cx43, accelerates healing in the treatment group.
Despite standard care with compression therapy and adjuvant therapy for
refractory wounds, at present in clinical practice a significant number of
patients remain unhealed. The potential for ACT1 exists to help heal refractory
VLUs, but it faces additional regulatory hurdles.
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